ArticleJournal of clinical medicine2022

Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19.

Prasenohadi Prasenohadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.